We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Method May Lower Costs Associated with HDL-CEC Measurements

By LabMedica International staff writers
Posted on 18 Sep 2019
Circulating high-density lipoprotein (HDL) particles mediate reverse cholesterol transport by carrying excess cholesterol from the periphery, such as the arterial wall, to the liver for excretion into the bile. More...
HDL-mediated cholesterol efflux capacity is a functional attribute that may have a protective role in atherogenesis.

Cholesterol efflux capacity of HDL (HDL-CEC), which quantifies the ability of HDL particles to extract cholesterol from lipid-laden cells, has emerged as the most widely used metric for HDL function. HDL-CEC reflects the combined action of various HDL particles via multiple cellular pathways. However, the estimation of HDL-CEC is based on in vitro cell assays that are laborious and hamper large-scale phenotyping.

Scientists at the University of Oulu (Oulu, Finland) and their colleagues collected random blood samples from the Finnish Red Cross blood service and serum was obtained by centrifugation at 1500g for 15 minutes at ambient temperature and stored at −80 °C. HDL-CEC was measured using cAMP-treated J774 cells within a year of sample collection. The same serum samples were also analyzed by proton nuclear magnetic resonance (NMR) spectroscopy within the same time frame. The complete training data set obtained comprised 199 individuals with the serum NMR spectra and the corresponding cellular in vitro HDL-CEC estimates. A high-throughput NMR spectroscopy platform with an optimized measurement protocol was used to provide quantitative information on the multiple molecular constituents of serum.

The team applied the new method in a population-based study of 7,603 individuals including 574 who developed incident coronary heart disease (CHD) during 15 years of follow-up, making this the largest quantitative study for HDL-CEC. As estimated by NMR-spectroscopy, a 1-SD higher HDL-CEC was associated with a lower risk of incident CHD (hazards ratio, 0.86; 95%CI, 0.79–0.93, adjusted for traditional risk factors and HDL-C). These findings are consistent with published associations based on in vitro cell assays.

The authors concluded that their method appears to have great potential to lower the experimental costs related to HDL-CEC measurements and concomitantly speed up collection of the extensive epidemiological evidence base necessary to ascertain whether this functional HDL phenotype is causal for vascular disease and, thus, whether it provides an opportunity for translational applications. The study was published in August 2019 issue of the journal Clinical Chemistry.

Related Links:
University of Oulu


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Graphical Abstract (Victori P, Hua K, Twigger AJ, et al. Tumor digital twins uncover therapeutic strategies in triple-negative breast cancer. Cell Reports Medicine, 2026. doi:10.1016/j.xcrm.2026.103119.)

Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. Its tumor cells lack estrogen receptors, progesterone receptors, and... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.